Efficacy and Safety of Combination Induction Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis: Results Through Week 12 of a Phase 2a Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, Proof-of-Concept Study.
出版信息
Gastroenterol Hepatol (N Y). 2022 Apr;18(4 Suppl 1):9-10.
Abstract
摘要
相似文献
1
Efficacy and Safety of Combination Induction Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis: Results Through Week 12 of a Phase 2a Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, Proof-of-Concept Study.古塞库单抗与戈利木单抗联合诱导治疗中度至重度活动性溃疡性结肠炎患者的疗效和安全性：一项2a期随机、双盲、活性对照、平行组、多中心概念验证研究第12周的结果
Gastroenterol Hepatol (N Y). 2022 Apr;18(4 Suppl 1):9-10.
2
Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).在中重度活动溃疡性结肠炎日本患者中，戈利木单抗 52 周维持治疗的疗效和安全性：一项 3 期、双盲、随机、安慰剂对照研究（PURSUIT-J 研究）。
J Gastroenterol. 2017 Oct;52(10):1101-1111. doi: 10.1007/s00535-017-1326-1. Epub 2017 Mar 21.
3
Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug-Drug Interactions.古塞库单抗与戈利木单抗联合治疗中度至重度活动性溃疡性结肠炎患者：药代动力学、免疫原性及药物相互作用
Clin Pharmacol Ther. 2024 Jun;115(6):1418-1427. doi: 10.1002/cpt.3235. Epub 2024 Mar 15.
4
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.依特利珠单抗用于中重度活动性溃疡性结肠炎患者的维持治疗（LAUREL）：一项随机、安慰剂对照、双盲、3 期研究。
Lancet Gastroenterol Hepatol. 2022 Jan;7(1):28-37. doi: 10.1016/S2468-1253(21)00295-8. Epub 2021 Nov 17.
5
7
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.依特利珠单抗与英夫利昔单抗治疗中重度活动性溃疡性结肠炎（GARDENIA）的随机、双盲、双模拟、3 期研究。
Lancet Gastroenterol Hepatol. 2022 Feb;7(2):118-127. doi: 10.1016/S2468-1253(21)00294-6. Epub 2021 Nov 17.
8
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.乌帕替尼作为中度至重度活动溃疡性结肠炎的诱导和维持治疗：三项 3 期、多中心、双盲、随机临床试验的结果。
Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26.
9
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.皮下注射戈利木单抗可维持中重度溃疡性结肠炎患者的临床应答。
Gastroenterology. 2014 Jan;146(1):96-109.e1. doi: 10.1053/j.gastro.2013.06.010. Epub 2013 Jun 14.
10
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.依特立珠单抗诱导和维持治疗中重度溃疡性结肠炎的疗效和安全性：一项随机、双盲、安慰剂对照的 3 期临床研究
Lancet Gastroenterol Hepatol. 2022 Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17.
引用本文的文献
1
Current Treatments, Emerging Therapeutics, and Natural Remedies for Inflammatory Bowel Disease.炎症性肠病的当前治疗方法、新兴治疗方法和天然疗法。
Molecules. 2024 Aug 21;29(16):3954. doi: 10.3390/molecules29163954.
2
IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy.IL-23 的过去、现在和未来：推进 IL-23 科学和治疗的路线图。
Front Immunol. 2024 Apr 15;15:1331217. doi: 10.3389/fimmu.2024.1331217. eCollection 2024.
3
Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease.PROMIS®-疲劳 SF-7a 量表评估中重度活动期炎症性肠病患者疲劳的定性和心理测量学评价。
J Patient Rep Outcomes. 2023 Nov 14;7(1):115. doi: 10.1186/s41687-023-00645-0.
4
Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies.炎症性肠病：新兴疗法与未来治疗策略
Biomedicines. 2023 Aug 11;11(8):2249. doi: 10.3390/biomedicines11082249.
5
Current and Emerging Targeted Therapies for Ulcerative Colitis.溃疡性结肠炎的当前及新兴靶向治疗方法
Visc Med. 2023 Jun;39(2):46-53. doi: 10.1159/000530983. Epub 2023 Jun 12.
6
Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease.双重生物疗法在炎症性肠病治疗中的新作用。
World J Clin Cases. 2023 Apr 26;11(12):2621-2630. doi: 10.12998/wjcc.v11.i12.2621.
7
Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis.类风湿关节炎和银屑病关节炎患者的双重生物制剂治疗
Rambam Maimonides Med J. 2023 Apr 30;14(2):e0007. doi: 10.5041/RMMJ.10494.
8
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease.白介素-12 和白介素-23 通路抑制在炎症性肠病中的作用。
Nat Rev Gastroenterol Hepatol. 2023 Jul;20(7):433-446. doi: 10.1038/s41575-023-00768-1. Epub 2023 Apr 17.
9
Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies.炎症性肠病的精准医学：生物制剂和小分子治疗药物的个体化应用。
World J Gastroenterol. 2023 Mar 14;29(10):1539-1550. doi: 10.3748/wjg.v29.i10.1539.
10
Cytokines in Spondyloarthritis and Inflammatory Bowel Diseases: From Pathogenesis to Therapeutic Implications.脊柱关节炎和炎症性肠病中的细胞因子：从发病机制到治疗意义。
Int J Mol Sci. 2023 Feb 16;24(4):3957. doi: 10.3390/ijms24043957.
本文引用的文献
1
Golimumab for the treatment of ulcerative colitis.戈利木单抗用于治疗溃疡性结肠炎。
Clin Exp Gastroenterol. 2014 Mar 12;7:53-9. doi: 10.2147/CEG.S48741. eCollection 2014.
Zotero 插件